Journal
DIAGNOSTIC AND INTERVENTIONAL IMAGING
Volume 101, Issue 9, Pages 577-588Publisher
ELSEVIER MASSON, CORP OFF
DOI: 10.1016/j.diii.2020.02.004
Keywords
Antigen presenting cell (APC); Fluorine-19 (19F); Cellular magnetic resonance imaging (MRI); Cancer immunotherapy
Funding
- Ontario Institute for Cancer Research Smarter Imaging Program [R4174419]
- Foundation Grant for Prostate Cancer Research [R2417A21]
- Dendreon Corporation [Proof of Concept Project] [R2417A20]
Ask authors/readers for more resources
Purpose. - The purpose of this study was to test fluorine-19 (19F) cellular magnetic resonance (MRI) as a non-invasive imaging modality to track therapeutic cell migration as a surrogate marker of immunotherapeutic effectiveness. Materials and methods. - Human peripheral blood mononuclear cell- (PBMC)-derived antigen presenting cell (APC) were labeled with a 19F-perfluorocarbon (PFC) and/or activated with granulocyte macrophage colony-stimulating factor (GM-CSF). Viability, phenotype and cell lineage characterization preceded 19F cellular MRI of PFC+ PBMC under both pre-clinical 9.4 Tesla (T) and clinical 3T conditions in a mouse model. Results. - A high proportion of PBMC incorporated PFC without affecting viability, phenotype or cell lineage composition. PFC+ PBMC were in vivo migration-competent to draining and downstream lymph nodes. GM-CSF addition to culture increased PBMC migration to, and persistence within, secondary lymphoid organs. Conclusion. - 19F cellular MRI is a non-invasive imaging technique capable of detecting and quantifying in vivo cell migration in conjunction with an established APC-based immunotherapy model. 19F cellular MRI can function as a surrogate marker for assessing and improving upon the therapeutic benefit that this immunotherapy provides. (C) 2020 L'Auteur(s). Publie par Elsevier Masson SAS au nom de Societe francaise de radiologie.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available